LUMABS BV develops Next-Generation immunoassays for clinical diagnostic applications. LUMABS BV is the first Bioluminescence diagnostic company with its proprietary Next-Generation bioluminescence-based homogenous immunoassay platform supporting quantitative, highly sensitive and rapid one-step biomolecule quantification in complex human samples that will revolutionize the way clinical diagnostic is performed.

Terug naar het overzicht